NCT05939310招募中不适用
Improving Radical Resection Rates in Patients With Breast Cancer by Intraoperative Imaging Using Bevacizumab-IRDye800CW - the MARGIN-2 Study
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 70
- 试验地点
- 4
- 主要终点
- Detection
研究概览
简要总结
The goal of this clinical trial is to intraoperatively visualize tumour tissue in breast cancer patients using fluorescence imaging with the tracer bevacizumab-IRDye800CW and thereby enhance real-time clinical decision making, preventing postoperative tumour-positive margins.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Patients are females with histologically proven carcinoma of the breast
- •The carcinoma of the breast is a local disease with limited size (but tumor size ≥ 0.5cm) and in the multidisciplinary tumor board meeting breast conserving therapy is advised.
- •Age ≥ 18 years
- •Written informed consent has been obtained
- •Women of childbearing potential (premenopausal women with intact reproductive organs and women less than two years after menopause) require use of effective contraception at least 3 months before administration of the tracer (if not, a negative serum pregnancy test has to be submitted), and they need to be willing to ensure that she or her partner uses effective contraception during the trial and for 3 months thereafter.
排除标准
- •Medical or psychiatric conditions that compromise the patient's ability to give informed consent
- •Non palpable breast tumor or prior surgery of this breast
- •Received an investigational drug within 30 days prior to bevacizumab-IRDye800CW
- •History of myocardial infarction, cerebrovascular accident, uncontrolled cardiac heart failure or unstable angina within 6 months prior to enrollment
- •Inadequately controlled hypertension with or without current antihypertensive medication
- •Significant renal or hepatic impairment (grade II or higher deviations by CTCAE)
- •History of allergy or infusion reactions bevacizumab or other monoclonal antibodies
- •Pregnant or lactating women
- •Patients receiving Class IA (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents
- •Life expectancy < 12 weeks
- •Preoperatively undetectable lymph nodes using SPECT-scan, requiring the use of patent blue
结局指标
主要结局
Detection
时间窗: 1 year
To determine whether real-time tumor visualization using targeted fluorescent imaging during breast conserving therapy in breast cancer patients can be achieved intraoperatively and results in adequate assessment of the tumor margin.
次要结局
- Radical resection rate(1 year)
- Detection in-vivo imaging(1 year)
- Detection ex-vivo imaging(1 year)
研究者
研究点 (4)
Loading locations...
相似试验
已完成
不适用
MarginProbe, a Device for Intraoperative Assessment of Margin Status in Breast Conservation SurgeryBreast CancerNCT00749931Dune Medical Devices664
已完成
不适用
Hypofractionated Image Guided Radiation Therapy in Treating Patients With Stage IV Breast CancerCentral Nervous System MetastasesInvasive Ductal Breast CarcinomaInvasive Ductal Breast Carcinoma With Predominant Intraductal ComponentInvasive Lobular Breast CarcinomaInvasive Lobular Breast Carcinoma With Predominant in Situ ComponentLiver MetastasesLobular Breast Carcinoma in SituLung MetastasesMedullary Ductal Breast Carcinoma With Lymphocytic InfiltrateMucinous Ductal Breast CarcinomaPapillary Ductal Breast CarcinomaRecurrent Breast CancerStage IV Breast CancerTubular Ductal Breast CarcinomaTumors Metastatic to BrainMale Breast CancerNCT01706432University of Chicago4
终止
不适用
Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast CancerStage IIA Breast CancerStage IIB Breast CancerStage IIIA Breast CancerStage IIIB Breast CancerStage IIIC Breast CancerStage IV Breast CancerNCT01897441Albert Einstein College of Medicine31
Unknown
1 期
The Breast Surgery EnLight and LightPath Imaging System StudyBreast NeoplasmsNCT02151071Lightpoint Medical Limited30
尚未招募
不适用
A Multicenter, RAndomIzed, coNtrolled, umBrella Trial fOr Minimally Invasive Neurosurgery With AI-assisted Robotic guidanCe for Hemorrhagic StrokeNCT06459427Yanbing Yu142